Samuel Rochette

Samuel Rochette

Auto-generated profile, based on publicly available information

Samuel Rochette

F Analysis Group, Inc , Montreal , QC , Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2019 in Journal of Medical Economics
Verified
Journal Article
Open access
BSBruce Spinowitz
Bruce Spinowitz
RPRoberto Pécoits-Filho
Roberto Pécoits-Filho
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
PPPablo E. Pergola
Pablo E. Pergola
SRSamuel Rochette
Samuel Rochette
HKHolly B. Krasa
Holly B. Krasa
Aims: The overall cost and health-related quality of life (HRQoL) associated with current treatments for chronic kidney disease (CKD)-related anemia are not well characterized. We conducted a systematic literature review (SLR) on the costs and HRQoL associated with current treatments for CKD-related anemia among dialysis-dependent (DD) patients. Material and methods: We searched the Cochrane Library, MEDLINE, EMBASE, NHS EED, and NHS HTA for English-language publications. Original studies published between 1/1/2000 and 3/17/2017 meeting the following criteria were included: adult population; study focus was CKD-related anemia; included results on patients receiving iron supplementation, red blood cell transfusion, or erythropoiesis stimulating agents (ESAs); reported results on HRQoL and/or costs. Studies which included patients with DD-CKD, did not directly compare different treatments, and had designs relevant to the objective were retained. HRQoL and cost outcomes, including healthcare resource utilization (HRU), were extracted and summarized in a narrative synthesis. Results: A total of 1,625 publications were retrieved, 15 of which met all inclusion criteria. All identified studies included ESAs as a treatment of interest. Two randomized controlled trials reported that ESA treatment improves HRQoL relative to placebo. Across eight studies comparing HRQoL of patients achieving high versus low hemoglobin (Hb) targets, aiming for higher Hb targets with ESAs generally led to modest HRQoL improvements. Two studies reported that ESA-treated patients had lower costs and HRU compared to untreated patients. One study found that aiming for higher versus lower Hb targets led to reduced HRU, while two other reported that this led to a reduction in cost-effectiveness. Limitations: Heterogeneity of study designs and outcomes; a meta-analysis could not be performed. Conclusions: ESA-treated patients undergoing dialysis incurred lower costs, lower HRU, and had better HRQoL relative to ESA-untreated patients. However, treatment to higher Hb targets led to modest HRQoL improvements compared to lower Hb targets.